Hangzhou Alltest Biotech Co., Ltd.

Shanghai Stock Exchange 688606.SS

Hangzhou Alltest Biotech Co., Ltd. Revenue for the year ending December 31, 2023: USD 106.30 M

Hangzhou Alltest Biotech Co., Ltd. Revenue is USD 106.30 M for the year ending December 31, 2023, a -78.35% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Hangzhou Alltest Biotech Co., Ltd. Revenue for the year ending December 31, 2022 was USD 491.04 M, a 66.54% change year over year.
Hangzhou Alltest Biotech Co., Ltd. Revenue for the year ending December 31, 2021 was USD 294.84 M, a 69.48% change year over year.
Hangzhou Alltest Biotech Co., Ltd. Revenue for the year ending December 31, 2020 was USD 173.97 M, a 401.99% change year over year.
Hangzhou Alltest Biotech Co., Ltd. Revenue for the year ending December 31, 2019 was USD 34.66 M, a 29.40% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

Shanghai Stock Exchange: 688606.SS

Hangzhou Alltest Biotech Co., Ltd.

CEO	Mr. Fei Gao
IPO Date	March 25, 2021
Location	China
Headquarters	#550, Yinhai Street
Employees	1,093
Sector	Health Care
Industries Biotechnology Chemicals & Advanced Materials Pharmaceuticals

Description

Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and market of in vitro diagnostic reagents worldwide. It offers rapid diagnostic products, including women's health, infectious diseases, drugs, cancer, cardiovascular, and other five series of products. The company is based in Hangzhou, China.

Key trends

Past 5 years